Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Male and female condoms.

BIBLIOGRAPHIC SOURCE(S)

  • Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Male and female condoms. London (UK): Faculty of Family Planning and Reproductive Health Care; 2007 Jan. 17 p. [144 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The recommendation grades (A to C, Good Practice Point) are defined at the end of the "Major Recommendations" field.

What Factors Should Be Considered When Choosing a Type of Condom?

Medical Eligibility Criteria: Sensitivity to Latex Proteins

  1. Men or women with sensitivity to latex proteins should avoid the use of latex condoms (Grade C).
  2. Men and women with sensitivity to latex may use male or female polyurethane condoms or deproteinised latex male condoms (Grade C).
  3. For men and women who have symptoms of local genital irritation associated with latex condom use, a clinical history should be taken to identify any cause. Further investigation may be warranted and referral considered (Good Practice Point).

Condoms Lubricated with Spermicide or Non-Spermicide

  1. The use of condoms lubricated with spermicide is not generally recommended (Grade B).

Condom Quality

  1. Condoms should be checked for relevant safety markings and a valid expiry date before use (Good Practice Point).

Use of Lubricant

  1. When using lubricant with latex condoms a non-oil-based preparation is recommended (Grade B).
  2. The use of lubricant is recommended for anal sex to reduce the risk of condom breakage (Grade B).
  3. It is not recommended that lubricant be applied to the penis under a male condom as this is associated with slippage (Grade B).

Condom Size, Shape and Thickness

  1. The use of a stronger (thicker) condom instead of standard condoms does not reduce the risk of breakage and is not generally recommended (Grade C).

How Effective Are Condoms at Preventing Pregnancy?

How Good Is the Evidence Available on Condoms in Preventing Pregnancy?

  1. Men and women can be advised that when used consistently and correctly, male condoms are up to 98% effective at preventing pregnancy (Grade C).
  2. Men and women can be advised that pregnancy rates are similar for latex and non-latex condoms (Grade A).

Contraceptive Efficacy of Female Condoms

  1. Men and women can be advised that when used consistently and correctly, female condoms are 95% effective at preventing pregnancy (Grade C).

How Effective Are Condoms at Preventing the Transmission of Sexually Transmitted Infections (STIs)?

What Factors Influence the Transmission of STIs?

  1. In general, evidence supports the use of condoms to reduce the risk of STIs. However, even with consistent and correct use, transmission may still occur (Grade C).

How Effective Are Condoms in Preventing the Transmission of Specific STIs?

Human Immunodeficiency Virus (HIV)

  1. The consistent and correct use of male latex condoms is recommended to reduce the risk of HIV transmission (Grade A).
  2. The consistent and correct use of female condoms and non-latex male condoms may be recommended to reduce the risk of HIV transmission (Good Practice Point).

Chlamydia Trachomatis

  1. The consistent and correct use of condoms is recommended to reduce the risk of C. trachomatis transmission (Grade B).

Neisseria Gonorrhoeae

  1. The consistent and correct use of male condoms is recommended to reduce the risk of N. gonorrhoeae transmission (Grade B).

Trichomonas Vaginalis

  1. The consistent and correct use of condoms is recommended to reduce the risk of transmission of T. vaginalis (Grade B).

Genital Herpes

  1. The consistent and correct use of male condoms is recommended to reduce the risk of transmission of herpes simplex virus (HSV) (Grade B).
  2. The consistent and correct use of female condoms may be advised to help reduce the risk of transmission of HSV (Good Practice Point).

Syphilis

  1. The consistent and correct use of male condoms is recommended to reduce the risk of syphilis transmission (Grade B).
  2. The consistent and correct use of female condoms may be advised to reduce the risk of syphilis transmission (Good Practice Point).

Human Papilloma Virus (HPV)

  1. The consistent and correct use of condoms is recommended to reduce the risk of transmission of genital HPV (Grade B).
  2. Male latex condoms, when used consistently and correctly, can increase the rate of HPV clearance and cervical intraepithelial neoplasia regression (Grade B).
  3. The consistent and correct use of female condoms may be advised to reduce the risk of transmission of genital HPV (Good Practice Point).

Viral Hepatitis

  1. Male latex condoms, when used consistently and correctly, may be recommended to reduce the risk of transmission of hepatitis B (Grade B).
  2. There is insufficient evidence to determine the efficacy of condoms in preventing transmission of hepatitis A and C. Use may be recommended during infectious episodes (Good Practice Point).

What Should Be Considered When There Is a Recognised or a Potential Condom Failure?

Emergency Contraceptive Use

  1. Advance provision of progestogen-only emergency contraception should be offered to women relying solely on condoms for contraception (Grade C).

Testing for STIs

  1. Men and women should be made aware of the possibility of STI when there is a potential condom failure and advised about STI testing 2 and 12 weeks later (Grade C).

Post-Exposure Prophylaxis for HIV

  1. Men and women can be made aware of post-exposure prophylaxis for HIV following sexual exposure (PEPSE) when there is a condom failure. The decision to initiate PEPSE can only be made after consideration of the risks of exposure and likelihood of compliance with treatment (Good Practice Point). See table below.

Table. Recommendations for Post-Exposure Prophylaxis Following Sexual Exposure (PEPSE) (e.g., Following Unprotected Sex or Condom Failure)

HIV Risk PEPSE Recommended PEPSE Considered PEPSE Not Recommended
Source is HIV positive Receptive anal and vaginal sex

Insertive anal and vaginal sex
Fellatio with ejaculation

Splash of semen into the eye
Fellatio without ejaculation

Cunnilingus
Source HIV status is unknown

Source from a group or area with high HIV prevalence (e.g., men who have sex with men, individuals from sub-Saharan Africa)
Receptive anal sex Receptive vaginal sex

Insertive anal and vaginal sex

Fellatio with ejaculation
 
Source not from a group or area of high HIV prevalence   Receptive anal sex Receptive vaginal sex

Insertive anal or vaginal sex

Fellatio with ejaculation

What Information Should Be Given About Condom Use?

  1. Counselling men and women about condoms should include advice on correct use, appropriate use of lubricant, STI screening and when emergency contraception may be required (Good Practice Point).

Note: Detailed instructions on the use of male condoms are provided in Box 1 in the original guideline document.

Note: Detailed instructions on the use of female condoms are provided in Box 2 in the original guideline document.

Definitions:

Grades of Recommendations

A: Evidence based on randomised controlled trials (RCTs)

B: Evidence based on other robust experimental or observational studies

C: Evidence is limited but the advice relies on expert opinion and has the endorsement of respected authorities

Good Practice Point: Where no evidence exists but where best practice is based on the clinical experience of the Multidisciplinary Group

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations" field).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Male and female condoms. London (UK): Faculty of Family Planning and Reproductive Health Care; 2007 Jan. 17 p. [144 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2007 Jan

GUIDELINE DEVELOPER(S)

Faculty of Sexual and Reproductive Healthcare - Professional Association

SOURCE(S) OF FUNDING

Faculty of Sexual and Reproductive Healthcare

GUIDELINE COMMITTEE

Clinical Effectiveness Unit

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Clinical Effectiveness Unit (CEU): Dr Susan Brechin, (CEU Unit Director); Ms Lisa Allerton (CEU Research Assistant); Ms Gillian Stephen, (CEU Research Assistant)

Clinical Effectiveness Committee: Mrs Walli Bounds (Former Research Co-ordinator, The Margaret Pyke Centre, London/Principal Research Fellow, Department of Obstetrics and Gynaecology, University College London (now retired); Dr David Hicks (Medical Director/Consultant in Genitourinary Medicine and HIV, Central Sheffield University Hospital/Representative of the FFPRHC Clinical Effectiveness Committee); Dr Nicola Mullin (Consultant in Sexual and Reproductive Health Care, Cheshire West PCT/Representative of the FFPRHC Education Committee); Dr Alyson Elliman (Consultant in Family Planning, Croydon PCT/Honorary Secretary of the FFPRHC); Mr Martin Murchie (Senior Health Adviser, The Sandyford Initiative, Glasgow); Mr Rod Watson (Deputy Head of Health Promotion, Terrence Higgins Trust, London); Dr Lesley Bacon (Consultant in Sexual Health, Lewisham PCT)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Faculty of Sexual and Reproductive Healthcare Web site.

Print copies: Available from the Faculty of Sexual and Reproductive Healthcare, 27 Sussex Place, Regent's Park, London NW1 4RG

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on May 16, 2008

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo